<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825263</url>
  </required_header>
  <id_info>
    <org_study_id>IMPRESS</org_study_id>
    <nct_id>NCT03825263</nct_id>
  </id_info>
  <brief_title>Intermittent Pneumatic Compression for Treating Lower Limb Lymphoedema</brief_title>
  <acronym>IMPRESS</acronym>
  <official_title>Intermittent Pneumatic Compression for Treating Lower Limb Lymphoedema: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cwm Taf University Health Board (NHS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Wales</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of lymphoedema and its associated complications represent a considerable drain&#xD;
      on increasingly limited NHS resources. Intermittent pneumatic compression, specifically the&#xD;
      LymphAssist (Huntleigh Healthcare), represents an innovative treatment for this condition but&#xD;
      the efficacy of this device needs to be investigated via robust clinical research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This feasibility study aims to evaluate a proposed methodology designed to assess the&#xD;
      efficacy of IPC in the treatment of lymphoedema. The study methodology consisted of a pilot&#xD;
      randomised control trial of IPC plus standard lymphoedema care versus standard lymphoedema&#xD;
      care alone. Feasibility outcomes included impact on lower limb volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">January 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Observational control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower Limb Volume</measure>
    <time_frame>3 and 6 months of treatment</time_frame>
    <description>Change in limb volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of IPC use on the Quality of Life: QOL Scores</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Change in QOL Scores. Using the Quality of LifeEnjoyment and Satisfication Questionairre short form (Q-LES-Q-SF) with 14 items. Score range is from 14 to 70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Perometer</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of limb volume measurement methods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lymphoedema</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive normal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Pressure Compression</intervention_name>
    <description>The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lymphassist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or over,&#xD;
&#xD;
          -  Able to provide written consent,&#xD;
&#xD;
          -  Confirmed diagnosis of lower limb ISL stage II or III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of these conditions&#xD;
&#xD;
          -  Severe congestive heart failure&#xD;
&#xD;
          -  Severe skin problems, lower limb ulcers or wounds.&#xD;
&#xD;
          -  Presence of cognitive impairment (permanent or intermittent) which would prevent&#xD;
             patients from using the IPC device safely or adhering to instructions/study protocol.&#xD;
&#xD;
          -  Non-pitting chronic lymphoedema.&#xD;
&#xD;
          -  Known or suspected deep vein thrombosis.&#xD;
&#xD;
          -  Pulmonary embolism.&#xD;
&#xD;
          -  Thrombophlebitis.&#xD;
&#xD;
          -  Acute inflammation of the skin (erysipelas, cellulitis).&#xD;
&#xD;
          -  Uncontrolled/severe cardiac failure.&#xD;
&#xD;
          -  Pulmonary oedema.&#xD;
&#xD;
          -  Ischaemic vascular disease.&#xD;
&#xD;
          -  Active cancer diagnosis.&#xD;
&#xD;
          -  Active metastatic diseases affecting the oedematous region.&#xD;
&#xD;
          -  Oedema at the root of the extremity or truncal oedema.&#xD;
&#xD;
          -  Severe peripheral neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Williams, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Wales</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dewi Sant Hospital</name>
      <address>
        <city>Pontypridd</city>
        <state>RCT</state>
        <zip>CF37 1LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

